Guidance for Demonstrating the Societal Value of new Antibiotics.

Given that antibiotic use is associated with externalities, standard economic evaluation which considers costs and health gains accruing to patients under-values antibiotics. Informed by a scoping review, this discussion paper aims to identify the societal value elements of antibiotics and to provide guidance on how these value elements can be incorporated in economic evaluation. With a view to appropriately quantify the societal value of antibiotics, there is a need for good practice guidelines on the methodology of economic evaluation for such products. We argue that it is important to assess antibiotics at population level to account for their transmission, diversity, insurance, spectrum, novel action and enablement values. In addition to the value of antibiotics to infected patients, economic evaluations need to use modeling approaches to explore the impact of different modes of employing new and existing antibiotics (for example, as last resort treatment) on disease transmission and resistance development in current and future patients. Hence, assessing the value of antibiotics also involves an ethical dimension. Further work is required about how the multiple value elements of antibiotics are linked to each other and how they can be aggregated.

Informations de copyright

Copyright © 2021 Simoens and Spriet.

Déclaration de conflit d'intérêts

SS has carried out health economic studies of antibiotics funded by Sanofi-Aventis, Bayer, TEVA, and the Belgian National Institute for Health and Disability Insurance. IS received unrestricted research grants from Pfizer and Merck, and travel support from Pfizer, Merck and Gilead.